脑内移植基因修饰细胞治疗帕金森病

Intracerebral transplantation of genetically modified cells for Parkinson's disease

由于供体来源困难,脑移植治疗帕金森病在临床上的应用受到限制。作者将酪氨酸羟化酶(TH)基因导入NIH-3T3细胞,这种经TH基因修饰的细胞,呈TH免疫组化阳性反应,并能产生左旋多巴。将其作为供体移植治疗帕金森病模型大鼠。移植后第3、6、9和12天,旋转行为分别改善52.6%、68.4%、63.2%、44.7%。作者认为,本实验结果具有潜在的临床应用价值。

The clinical application of brain transplantation for treating Parkinson's disease(PD) is limited because it is difficult to obtain ideal donor cells. In this study, the tyrosine hydroxylase(TH) gene was intrduced into NIH-3T3 cell line and the genetically modified cells reacted positively with TH antiserum and released L-dopa. These cells were implanted into the striatum of PD rats. 3, 6, 9, 12 days after implantation, the average rate of the abnormal rotational behavior recovery was 52.6% 68.4%, 63.2%, 44.7%, respectively. This result is considered to be potential for further clinical application.